Literature DB >> 22396197

Clinical trials of HDL cholesterol-raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH?

Robert S Rosenson1.   

Abstract

Entities:  

Year:  2012        PMID： 22396197     DOI： 10.1007/s11883-012-0236-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  14 in total

1.  Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Authors:  Laurent Yvan-Charvet; Jelena Kling; Tamara Pagler; Hongna Li; Brian Hubbard; Tim Fisher; Carl P Sparrow; Andrew K Taggart; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

2.  Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.

Authors:  Hong Chang Tan; E Shyong Tai; Dmitri Sviridov; Paul J Nestel; Cindy Ng; Edmund Chan; Yvonne Teo; Daniel Chun Hang Wai
Journal:  J Clin Lipidol       Date:  2011-06-28       Impact factor: 4.766

Review 3.  Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

Authors:  Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet
Journal:  Circulation       Date:  2012-04-17       Impact factor: 29.690

4.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.

Authors: 
Journal:  Am Heart J       Date:  2011-02-02       Impact factor: 4.749

7.  Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids.

Authors:  Ben J Wu; Ling Yan; Francesca Charlton; Paul Witting; Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-18       Impact factor: 8.311

8.  Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.

Authors:  Benjamin J Ansell; Mohamad Navab; Susan Hama; Naeimeh Kamranpour; Gregg Fonarow; Greg Hough; Shirin Rahmani; Rachel Mottahedeh; Ravi Dave; Srinivasa T Reddy; Alan M Fogelman
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

9.  Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.

Authors:  Subha L Airan-Javia; Ronald L Wolf; Megan L Wolfe; Mahlet Tadesse; Emile Mohler; Muredach P Reilly
Journal:  Am Heart J       Date:  2009-02-23       Impact factor: 4.749

10.  Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.

Authors:  Robert S Rosenson; James D Otvos; Judith Hsia
Journal:  Diabetes Care       Date:  2009-03-05       Impact factor: 19.112
View more
  3 in total

1.  When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events.

Authors:  Robert S Rosenson; Antonio M Gotto
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

2.  Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease.

Authors:  William Hancock-Cerutti; John S Millar; Silvia Valentini; Jason Liu; Jeffrey T Billheimer; Daniel J Rader; Marina Cuchel
Journal:  Molecules       Date:  2021-11-14       Impact factor: 4.411

Review 3.  GPR109A and vascular inflammation.

Authors:  Joshua T Chai; Janet E Digby; Robin P Choudhury
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.